DENTSPLY SIRONA (NASDAQ:XRAY) Shares Down 7.5% – Should You Sell?

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) fell 7.5% during trading on Friday . The stock traded as low as $12.31 and last traded at $12.33. 662,151 shares were traded during mid-day trading, a decline of 87% from the average session volume of 4,911,188 shares. The stock had previously closed at $13.33.

Analyst Ratings Changes

XRAY has been the topic of a number of research reports. Mizuho increased their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. UBS Group lowered their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Barclays initiated coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective for the company. Finally, Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $14.42.

DENTSPLY SIRONA Stock Performance

The business’s 50-day simple moving average is $12.63 and its two-hundred day simple moving average is $12.47. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -4.25, a P/E/G ratio of 1.49 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. DENTSPLY SIRONA’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were given a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 5.0%. DENTSPLY SIRONA’s payout ratio is -21.33%.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is currently owned by insiders.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of DENTSPLY SIRONA during the first quarter worth about $26,000. Goldman Sachs Group Inc. lifted its stake in DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares in the last quarter. Empowered Funds LLC lifted its stake in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after buying an additional 41,579 shares during the last quarter. Finally, Focus Partners Wealth increased its stake in DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.